OlayemiOlajideOsiyemiMD

Infectious Disease • West Palm Beach, FL

President/CEO at Triple O Medical Services PA, Triple O Research Institute PA, Fantastic Wellness Center

Join to view full profile

Dr. Osiyemi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Osiyemi's full profile

Already have an account?

Office
2580 Metrocentre Blvd
Ste 3
West Palm Beach, FL 33407
Phone+1 561-832-6770

Fax+1 561-832-3292
Is this information wrong?

Summary

Dr. Olayemi Osiyemi is an infectious disease specialist in West Palm Beach, FL and is affiliated with multiple hospitals in the area, including St. Mary’s medical center, Good Samaritan medical center, Kindred Hospital Of the Palm Beach and JFK Medical Center. He received his medical degree from University of Maryland School of Medicine and has been in practice 20 years. He is the President of Triple O Medical Services and Triple O Tesearch Institute PA. He is involved in all phases of clinical trials and has published in several peer reviewed journals. He has a phase I unit in his research organization. He hold several leadership positions and serves on several boards. He also co-owns Fantastic wound care and Wellness Center in west palm beach, FL.

Education & Training

University of Miami/Jackson Health SystemFellowship, Infectious Disease, 2000
University of Miami/Jackson Health SystemResidency, Internal Medicine, 1995 - 1998
University of Miami/Jackson Health SystemInternship, Internal Medicine, 1995 - 1996
University of Maryland School of MedicineClass of 1995
Jacksonville State UniversityB.S., Chemistry and Mathematics, 1982 - 1985

Certifications & Licensure

FL State Medical License 1997 - 2025
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
100 Most Influential African American South Florida, 2009
Certificate of Appreciation The Department of Health of Palm Beach County, 2008
Certificate of Appreciation Worlds AIDS Day/FL Health Dept of Palm Beach County, 2005, 2008
Certificate of Appreciation Palm Beach County Medical Society, 2004, 2007
Citizen of the Year in Palm Beach County Minority Law Enforcement Council, 2003
Physician of the Month St. Mary's Medical Center, 2003
President's Certificate of Commendation University of Maryland at Baltimore, 1993
Good Conduct Medal U.S. Army, 1990
Commendation Medal Award U.S. Army, 1990
Commendation Award United Way, 1987
Join now to see all

Clinical Trials

Study of KP-1461 for the Treatment of HIV Positive Patients Who Have Failed Multiple HAART Regimens Start of enrollment: 2005 Aug 01
Completed
Phase 1
SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients Start of enrollment: 2006 Mar 01
Unknown status
Phase 2
Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation Start of enrollment: 2006 Mar 31
Completed
Phase 1, Phase 2
Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women Start of enrollment: 2006 Jun 01
Completed
Phase 1
Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants Start of enrollment: 2006 May 01
Completed
Phase 2
Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients Start of enrollment: 2006 Jul 01
Completed
Phase 3
Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir Start of enrollment: 2007 Jun 01
Completed
Phase 3
Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1 Start of enrollment: 2008 Aug 01
Completed
Phase 2
An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options. Start of enrollment: 2004 May 01
Approved for marketing
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus Start of enrollment: 2011 Jun 01
Completed
Phase 2
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Start of enrollment: 2013 Feb 01
Terminated
Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay Start of enrollment: 2014 Mar 01
Completed
Study of Debio 1450 for Bacterial Skin Infections Start of enrollment: 2015 May 01
Completed
Phase 2
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV Start of enrollment: 2015 Aug 01
Completed
Phase 3
Antibiotic Prophylaxis in Open Fractures Start of enrollment: 2016 Dec 01
Unknown status
Phase 4
Preventing Infections in Orthopaedic Patients Start of enrollment: 2016 Nov 01
Unknown status
Join now to see all

Publications & Presentations

PubMed

Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.
De Wit, S., Bonnet, F., Osiyemi, O., Bisshop, F., Olalla, J., Routy, J., Wyen, C., Moodley, R., Pappa, K., Wang, R., Oyee, J., Saggu, P., Letang, E., Wynne, B., Jones,...> ;Journal of Acquired Immune Deficiency Syndromes. 2024 Mar 1
3 citations
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir ala...
Moti N Ramgopal, Antonella Castagna, Charles Cazanave, Vicens Diaz-Brito, Robin Dretler, Shinichi Oka, Olayemi Osiyemi, Sharon Walmsley, James Sims, Giovanni Di Perri,...> ;The Lancet. HIV. 2023 Sep 1
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppressi...
Olayemi Osiyemi, Stéphane De Wit, Faïza Ajana, Fiona Bisshop, Joaquín Portilla, Jean Pierre Routy, Christoph Wyen, Mounir Ait-Khaled, Peter Leone, Keith A Pappa, Ruola...> ;Clinical Infectious Diseases. 2022 Sep 29
6 citations
Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study.
Steven E Coutre, Christopher Barnett, Olayemi Osiyemi, Daanish Hoda, Moti Ramgopal, Alexander C Fort, Roula Qaqish, Yiran Hu, Joi Ninomoto, Negar N Alami, Lori Styles,...> ;Open Forum Infectious Diseases. 2022 May 1
33 citations
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults...
Josep M Llibre, Carlos Brites, Chien-Yu Cheng, Olayemi Osiyemi, Carlos Galera, Laurent Hocqueloux, Franco Maggiolo, Olaf Degen, Stephen Taylor, Elizabeth Blair, Choy M...> ;Clinical Infectious Diseases. 2023 Feb 18
6 citations
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV: a randomized phase 3 study.
Lerato Mohapi, Yvett Pinedo, Olayemi Osiyemi, Khuanchai Supparatpinyo, Winai Ratanasuwan, Jean-Michel Molina, Ron Dagan, Gretchen M. Tamms, Tina M. Sterling, Ying Zhan...> ;AIDS. 2021 Nov 22
11 citations
Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression: pOLAR month 12 results.
Anthony M. Mills, Gary Richmond, Cheryl L. Newman, Olayemi Osiyemi, Jerry Cade, Cynthia Brinson, Jerome De Vente, David A. Margolis, Kenneth Sutton, Viviana Wilches, S...> ;AIDS. 2021 Oct 13
11 citations
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
Debbie Hagins, Princy Kumar, Michael S. Saag, Anson K Wurapa, Indira Brar, Daniel S Berger, Olayemi Osiyemi, Corrilynn O. Hileman, Moti Ramgopal, Cheryl McDonald, Chri...> ;Journal of Acquired Immune Deficiency Syndromes. 2021 Sep 1
138 citations
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance ...
Jean van Wyk, Faiza Ajana, Fiona Bisshop, Stéphane De Wit, Olayemi Osiyemi, Joaquín Portilla Sogorb, Jean-Pierre Routy, Christoph Wyen, Mounir Ait-Khaled, Maria Claudi...> ;Clinical Infectious Diseases. 2020 Nov 5
19 citations
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.
José M. Gatell, Javier O Morales-Ramirez, Debbie Hagins, Melanie A. Thompson, Keikawus Arastéh, Christian Hoffmann, François Raffi, Olayemi Osiyemi, Robin Dretler, Cha...> ;Antiviral Therapy. 2019 Jan 1
18 citations
Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen.
Herta Crauwels, Olayemi Osiyemi, Carmen D. Zorrilla, C Bicer, Kimberley Brown> ;HIV Medicine. 2019 May 1
Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, F...
Hagins, D.,Orkin, C.,Daar, E. S.,Mills, A.,Brinson, C.,DeJesus, E.,Post, F. A.,Morales-Ramirez, J.,Thompson, M.,Osiyemi, O.,Rashbaum, B.,Stellbrink, H. J.,Martorell, C...> ;HIV Med.. 2018 Aug 14
16 citations
Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study
Olayemi Osiyemi, Salih Yasin, Carmen D. Zorrilla, Ceyhun Bicer, Vera Hillewaert, Kimberley Brown, Herta Crauwels> ;Infectious Diseases and Therapy. 2018 Jan 15
10 citations
Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women.
Moti Ramgopal, Olayemi Osiyemi, Carmen D. Zorrilla, Herta Crauwels, R Ryan, Kimberley Brown, Vera Hillewaert, Bryan Baugh> ;Journal of Acquired Immune Deficiency Syndromes. 2016 Nov 1
19 citations
Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women
Herta Crauwels, Thomas N. Kakuda, B. Ryan, Carmen D. Zorrilla, Olayemi Osiyemi, Salih Yasin, Kimberley Brown, P Verboven, Vera Hillewaert, Bryan Baugh> ;HIV Medicine. 2016 May 1
126 citations
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment ...
Joel E. Gallant, Eric S. Daar, François Raffi, Cynthia Brinson, Peter Ruane, Edwin DeJesus, Margaret Johnson, Nathan Clumeck, Olayemi Osiyemi, Doug Ward, Javier O Mora...> ;The Lancet. HIV. 2016 Apr 1
7 citations
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded...
Samir K. Gupta, Grace A. McComsey, John Lombaard, Juan Echevarria, Catherine Orrell, Anchalee Avihingsanon, Olayemi Osiyemi, Mario Santoscoy, Neelanjana Ray, David A. ...> ;The Lancet. HIV. 2016 Jan 1
11 citations
Antibiotic susceptibilities of bacteria isolated within the oral flora of Florida blacktip sharks: guidance for empiric antibiotic therapy.
Nathan R. Unger, Erich K. Ritter, Robert Borrego, Jay Goodman, Olayemi O. Osiyemi> ;Plos One. 2014 Aug 11
6 citations
Clinical and Pharmacogenetic Factors Affecting Neonatal Bilirubinemia Following Atazanavir Treatment of Mothers During Pregnancy
Timothy Eley, Shu-Pang Huang, Francesca Conradie, Carmen D. Zorrilla, Deirdre Josipovic, Mariette E. Botes, Olayemi Osiyemi, Helene Hardy, Richard Bertz, Donnie McGrath> ;AIDS Research and Human Retroviruses. 2013 Sep 27
13 citations
Effects of Darunavir/Ritonavir-Based Therapy on Metabolic and Anthropometric Parameters in Women and Men Over 48 Weeks
Judith S. Currier, Claudia Martorell, Olayemi Osiyemi, Michael T. Yin, Robert Ryan, Guy De La Rosa, Joseph M. Mrus> ;AIDS Patient Care and Stds. 2011 May 25
Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.
Currier, J., Averitt Bridge, D., Hagins, D., Zorrilla, C. D., Feinberg, J., Ryan, R., Falcon, R., Tennenberg, A., Mrus, J., Squires, K.> ;Ann Intern Med. 2010 Sep 21
36 citations
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
Edwin DeJesus, Jacob Lalezari, Olayemi Osiyemi, Peter Ruane, Robert Ryan, Thomas N. Kakuda, James Witek> ;Antiviral Therapy. 2010 Jul 1
29 citations
Cerebral phaeohyphomycosis due to a novel species: report of a case and review of the literature.
Olayemi O. Osiyemi, Lorraine Dowdy, Stephen Mallon, Timothy Cleary> ;Transplantation. 2001 May 15
5 citations
Gram-Positive Pneumonia.
Olayemi O. Osiyemi, Gordon M. Dickinson> ;Current Infectious Disease Reports. 2000 Jun 1
Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
Conradie, F., Zorrilla, C., Josipovic, D., Botes, M., Osiyemi, O., Vandeloise, E., Eley, T., Child, M., Bertz, R., Hu, W., Wirtz, V., McGrath, D.> ;HIV Med. 2011 Oct
Join now to see all

Journal Articles

Switching to Coformulated Rilpivirine (RPV), Emtricitabine (FTC) and Tenofovir Alafenamide from Either RPV, FTC and Tenofovir Disoproxil Fumarate (TDF) or Efavirenz, F...
E S Daar, O Osiyemi, D Porter, M Thompson, C Martorell, HIV Medicine
Ceftaroline and gentamicin for the treatment of daptomycin-non-susceptible methicillin-resistant Staphylococcus aureus bacteremia and endocarditis in a pregnant patient
Nathan R. Unger, Olayemi Osiyemi, Robert M. Richardson, Jose Menajovsky and Jennifer Kuretsk, JMM Caser Reports, 1/1/2014
Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100mg administered twice daily
CD Zorrilla, R Wright, OO Osiyemi, et al, HIV Medicine. Short Communications, 1/1/2013
Effects of Darunavir/Ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks
J. Currier, C. Martorell, O. Osiyemi, M. Yin, R. Ryan, G. De La Rosa, and J. Mrus, AIDS Patient Care & STDs, 1/1/2011
Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women
F. Conradie, C. Zorilla, D. Josipovic, M. Botes, O. Osiyemi, E. Vandeloise, etc., British HIV Association, 1/1/2011
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naïve HIV type-1-infected adults
E. DeJesus, J. Lalezari, O. Osiyemi, P. Ruane, R. Ryan, T. Kakuda, J. Witek, Antiviral Therapy, 1/1/2010
Gram-positive pneumonia
Osiyemi O. and Dickinson G, Current Infectious disease reports, 1/1/2000
Epidemiologic studies & characterization of Vancomycin- resistant Enterococci recovered from a University Hospital
P. Verma, J.G. Morris, J. Hebden, Y. Smith, O. Osiyemi, M. Fullem, and R. Schwalbe, University of Maryland, 1/1/1994
Characterization of the Recombinant 47kilodalton Protein Antigen of Rickettsia tsutsugamushi expressed in Escherichia coli
E.V. Oaks, O. Osiyemi and C.K. Stover, Walter Reed Army Institute of Research, 1/1/1989
Join now to see all

Abstracts/Posters

BMS-986001 in Antiretroviral-Naïve Subjects: Evaluation of Bone and Metabolic Safety Data Through Week 48.
GA McComsey, S Guta, C Orrell, A Avihingsanon, O Osiyemi, D Stock, N Ray, SR Joshi, GJ Hanna, M Lataillade, ICAAC, 1/1/2014
Total and Unbound Darunavir (DRV) Pharmacokinetics (PK) in HIV-1 Infected Pregnant Women.
Carmen Zorrilla, Rodney Wright, Olayemi Osiyemi, Salih Yasin, et al, CROI, Seattle, WA, 3/5/2012
GRACE (Gender, Race And Clinical Experience): effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks.
J. Currier, C. Martorell, O. Osiyemi, M. Yin, R. Ryan, G. De La Rosa and J. Mrus., International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (ADRL), Philadelphia, PA, 10/26/2009
Pharmacokinetics and Short-term Safety and Efficacy of Once-daily Etravirine Without and With Once-daily Darunavir/ritonavir in Antiretroviral-naïve HIV-1 Infected Adu...
J. Lalezari, E. DeJesus, O. Osiyemi, P. Ruane, R. Ryan, B. Polsonetti, T. Kakuda, J. Witek, HIV DART, Rio Mar Beach, PR, 12/9/2008
Pharmacokinetics of Once-Daily Etravirine (ETR) Without and With Once-Daily Darunavir/Ritonavir (DRV/r) in Antiretroviral-Naïve HIV-1 Infected Adults.
J. Lalezari, E. DeJesus, O. Osiyemi, P. Ruane, Z. Haigney, R. Ryan, B. Polsonetti, T. Kakuda, J. Witek, Ninth International Congress on Drug Therapy in HIV Infection (HIV9), Glasgow, UK, 11/9/2008
Cerebral Phaeohyphmycosis due to a novel species.
O. Osiyemi, L. Dowdy, A. Padhye, T. Cleary and S. Mallon, University of Miami and Center for Disease Control & Prevention, 1/1/1999
Characterization of Vibrio cholerae strains by pulse field electrophoresis.
M. Trucksis, Y. Deng and O. Osiyemi, Center for Vaccine Development, University of Maryland at Baltimore, Baltimore, MD, 1/1/1995
Join now to see all

Lectures

Total and unbound pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.
1/1/2014
Total and unbound darunavir pharmacokinetics in HIV-1-infected pregnant women.
Toronto, Canada - 1/14/2013

Press Mentions

'More and More' COVID-19 Cases Expected with Holidays Ahead, Doctor SaysMay 23rd, 2022
Health Care Workers 'Stressed Out' Battling COVID-19 ResurgenceAugust 4th, 2021
On the Front Lines: Unvaccinated Health Workers Put Floridians at RiskJuly 30th, 2021
Join now to see all